Post-transplant lymphoproliferative disorders

Stephen Gottschalk, Cliona M. Rooney, Helen E. Heslop

Research output: Contribution to journalReview articlepeer-review

373 Scopus citations


Post-transplant lymphoproliferative disorder (PTLD) is a life-threatening complication after hematopoietic stem cell or solid organ transplantation. The majority of PTLD is of B-cell origin and associated with Epstein-Barr virus (EBV). During the past decade progress has been made in better understanding the pathogenesis of PTLD, and early detection strategies, such as serial measurement of EBV-DNA load in peripheral blood samples, have assisted in the identification of high-risk patients. In addition, novel immunotherapies have been developed, including the use of monoclonal antibodies and adoptive transfer of EBV-specific T cells. Despite these advances, it remains a major challenge to define indications for preemptive therapies for PTLD and to integrate novel therapeutic approaches with conventional therapies.

Original languageEnglish (US)
Pages (from-to)29-44
Number of pages16
JournalAnnual Review of Medicine
StatePublished - 2005


  • Epstein-Barr virus
  • Hematopoietic stem cell transplant
  • Immunotherapy
  • Lymphoma
  • Solid organ transplant

ASJC Scopus subject areas

  • Cell Biology
  • Medicine(all)


Dive into the research topics of 'Post-transplant lymphoproliferative disorders'. Together they form a unique fingerprint.

Cite this